How Will Recent Safety Concerns Affect PPAR-Gamma Agonists?Decision ResourcesJune 25, 2007 20 Pages - SKU: DECR1507384 |
|
Freedonia Focus on Diabetes Monitoring Products: United States
5/31/2012 | published by: Freedonia Focus
This report discusses US demand for diabetes monitoring products for the years 2006 and 2011, with forecasts for 2016. Topics covered include market size, product and market segmentation, regulatory considerations, product development, market environment, product
|
more...
|
$600.00
|
|
Out-of-Pocket Healthcare 2012
4/3/2012 | published by: Kalorama Information
Despite numerous attempts to reign in costs of healthcare, consumers are increasingly paying for healthcare products and services from their own monies. The costs of health care products and services continue
|
more...
|
$995.00
|
|
Targeted Health and Wellness Foods and Beverages: The U.S. Market and Global Trends
3/1/2012 | published by: Packaged Facts
The market for targeted health and wellness foods and beverages is a dynamic and promising one, driven largely by the growing recognition—among scientists, government, practitioners, and consumers alike—of the instrumental role diet plays in a
|
more...
|
$3,500.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Diabetic Retinopathy Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Diabetic Retinopathy Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Diabetic Retinopathy Global Clinical Trials Review, H1, 2012 provides data on the Diabetic Retinopathy clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Canada Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: With Canada’s economy set to weather the external storm, the outlook for the country’spharmaceutical market looks relatively stable. Over the longer-term an ageing population in this alreadymature market should support spending. We also
|
more...
|
$1,175.00
|
|
Kuwait Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: While Kuwait will continue to be of interest to multinational drugmakers – on account oftraditional preference for branded medicines and the population’s wealth – we caution that strengtheningregional harmonisation will make for an
|
more...
|
$1,175.00
|
|
Spain Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: Companies with significant exposure to debt-ridden European markets will be hard hit bygovernment austerity measures across the region, particularly by pharmaceutical price erosionmechanisms. The Spanish government’s austerity measures look set to continue to
|
more...
|
$1,175.00
|
|
West and Central Africa Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: The better regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israelwill remain the most rewarding and least risky for drugmakers operating in the Middle East and Africa(MEA). However, these markets
|
more...
|
$1,175.00
|
|
China Pharmaceutical Industry Research and Forecast to 2016
3/1/2012 | published by: AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms of patented drugs, generic drugs, OTC drug and even sub-segments
|
more...
|
$700.00
|
Related Markets
Prescription Drugs Reports
- Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Chinese Markets for Hepatitis Drugs
- Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
